Skip to main content

Table 4 Characteristics and recent treatments/conditions of patients with anti-IL-1therapy discontinuation for various reasons

From: Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

 AgeSexMutationDominant clinical features and the Reasons for Discontinuation of Anti-IL1 TreatmentDuration of Using Anti-IL-1 agentsRecent treatments/conditions
Patient 121FM694 V homozygousAmyloidosis Stage 5 CRD 11 g/day proteinuriaİncrease of proteinuria, Progression of CRDAnakinra/12 monthsRenal tx
Patient 228MM694 V heterozygous
M680I heterozygous
PAN+sacroiliitisActivation of PAN/high dose corticosteroidAnakinra/12 monthsSepsis-died
Patient 325MM694 V heterozygous
M680I heterozygous
Sacroiliitisrefractory low back pain
high BASDAI score
Canakinumab/4 monthsAnti-TNF
Patient 424MM694 V homozygousSacroiliitisrefractory low back pain
high BASDAI score
Canakinumab/6 monthsAnti-TNF
Patient 550MR761H homozygousSacroiliitis+polyarthritisRefractory arthritisCanakinumab/18 months (secondary non-responder)Tocilizumab
Patient 619MM680I homozygousPeripheral ArthritisRefractory arthritisAnakinra/3 monthsTocilizumab
Patient 749MM694 V homozygousAmyloidosis
Stage 4 CRD
2.5 g/day proteinuria
İncrease of proteinuriaCanakinumab/4 monthsTocilizumab
Patient 845FM694 V heterozygous Side effectAnakinra/2 yearsMultiple sclerosis-drug stop
  1. PAN polyarteritis nodosa, CRD Chronic Renal Disease, Renal tx renal transplant, (BASDAI) Bath Ankylosing Spondylitis Disease Activity Index, TNF Tumour necrosis factor, IL interleukin